(Q24248714)

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

The treatment of idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Fibroblast chemotactic response elicited by native bronchoalveolar lavage fluid from patients with fibrosing alveolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

High dosages of D-penicillamine in pulmonary fibroses (author's transl)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Determinants of progression in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy. Implications for further studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Effect of cyclosporin A on inflammatory cytokine production by human alveolar macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Bronchoalveolar lavage fluid cell counts in cryptogenic fibrosing alveolitis and their relation to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Cyclosporin as a treatment for interstitial lung disease of unknown aetiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Interstitial lung disease resistant to corticosteroid therapy. Report of three cases treated with azathioprine or cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Diffuse interstitial pneumonitis. Clinicopathologic correlations in 20 patients treated with prednisone/azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Nonsteroidal therapy for idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Interferon gamma-1b therapy for cryptogenic fibrosing alveolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Cryptogenic fibrosing alveolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

NHLBI Workshop summary. Current concepts in idiopathic pulmonary fibrosis: a road map for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Anticytokine approaches in pulmonary fibrosis: bringing factors into focus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Pulmonary fibrosis: cytokines in the balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Cyclophosphamide in the treatment of pulmonary diseases: survey of use, training, and practitioner knowledge base

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Interstitial lung disease: current concepts of pathogenesis, staging and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Determinants of survival in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Epstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Does the treatment of cryptogenic fibrosing alveolitis influence prognosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Viruses and idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

New treatments for pulmonary fibrosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Potential therapeutic initiatives for fibrogenic lung diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Idiopathic Pulmonary Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Acute respiratory failure after interferon-gamma therapy of end-stage pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Exposure to commonly prescribed drugs and the etiology of cryptogenic fibrosing alveolitis: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Oxidants/antioxidants in idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Lung toxicity associated with cyclophosphamide use. Two distinct patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: A prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Idiopathic pulmonary fibrosis: current concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Diffuse fibrosing alveolitis (diffuse interstitial fibrosis of the lungs): Correlation of histology at biopsy with prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Transbronchial biopsy and needle aspiration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Cryptogenic fibrosing alveolitis: clinical features and their influence on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

UICC-Cincinnati classification of the radiographic appearances of pneumoconioses. A cooperative study by the UICC committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Colchicine Versus Prednisone as Treatment of Usual Interstitial Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Occupational and Environmental Risk Factors for Idiopathic Pulmonary Fibrosis: A Multicenter Case-Control Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

Efficacy of cyclosporin A for idiopathic pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

7 January 2021

Therapy of the idiopathic fibrosis of the lung

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

7 January 2021

[D-penicillamine in the treatment of pulmonary fibrosis (author's transl)]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

7 January 2021

Pirfenidone in idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

7 January 2021

Comparative study on effects of pentoxifylline, prednisolone and colchicine in experimental alveolitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

7 January 2021

Advanced cryptogenic fibrosing alveolitis: preliminary report on treatment with cyclosporin A

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

7 January 2021

Natural History and Treated Course of Usual and Desquamative Interstitial Pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

7 January 2021

Interferon gamma-1b for the treatment of idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

7 January 2021

Early stage of fulminant idiopathic pulmonary fibrosis cured by intense combination therapy using cyclophosphamide, vincristine, and prednisone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

7 January 2021

Different Therapies and Factors Influencing Response to Therapy in Idiopathic Diffuse Fibrosing Alveolitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

7 January 2021

Pharmacologic suppression of the neutrophil component of the alveolitis in idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

7 January 2021

Colchicine suppresses the release of fibroblast growth factors from alveolar macrophages in vitro. The basis of a possible therapeutic approach ot the fibrotic disorders

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

7 January 2021

Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

7 January 2021

Azathioprine Combined with Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis: A Prospective Double-blind, Randomized, Placebo-controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

7 January 2021

The epidemiology of interstitial lung diseases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

7 January 2021

Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

7 January 2021

Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

7 January 2021

Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

7 January 2021

Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

7 January 2021

A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

7 January 2021

American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

7 January 2021

Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

7 January 2021

Histopathologic variability in usual and nonspecific interstitial pneumonias

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

7 January 2021

Nonspecific interstitial pneumonia-nobody said it's perfect

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

7 January 2021

New approaches to the treatment of pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

7 January 2021

The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

7 January 2021

Cyclophosphamide pulse therapy in idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

7 January 2021

Colchicine in the treatment of pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

7 January 2021

Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

7 January 2021

Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003134

7 January 2021

10.1002/14651858.CD003134

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

2861695

OpenCitations bibliographic resource ID

2861695

1 reference